Cancer Therapy Due to Apoptosis: Galectin-9
暂无分享,去创建一个
Tsutomu Masaki | Takako Nomura | Teppei Sakamoto | T. Masaki | Tomoko Tadokoro | A. Morishita | H. Iwama | Koji Fujita | K. Oura | Teppei Sakamoto | T. Nomura | J. Tani | Hirohito Yoneyama | T. Himoto | M. Hirashima | Mitsuomi Hirashima | Koji Fujita | Hisakazu Iwama | Kyoko Oura | Tomoko Tadokoro | Eri Samukawa | Joji Tani | Hirohito Yoneyama | Asahiro Morishita | Takashi Himoto | Eri Samukawa
[1] N. Sharon,et al. Lectins as cell recognition molecules. , 1989, Science.
[2] L. Baum,et al. Clusters, bundles, arrays and lattices: novel mechanisms for lectin-saccharide-mediated cellular interactions. , 2002, Current opinion in structural biology.
[3] Jian-nan Feng,et al. The N- and C-terminal carbohydrate recognition domains of galectin-9 contribute differently to its multiple functions in innate immunity and adaptive immunity. , 2011, Molecular immunology.
[4] T. Niki,et al. Galectin-9 in cancer therapy. , 2013, Recent patents on endocrine, metabolic & immune drug discovery.
[5] William S York,et al. Regulation of Glycan Structures in Animal Tissues , 2008, Journal of Biological Chemistry.
[6] Sandra,et al. Profiling Lgals 9 Splice Variant Expression at the Fetal-Maternal Interface : Implications in Normal and Pathological Human Pregnancy 1 , 2013 .
[7] T. Yoshii,et al. Endogenous Galectin-3 Determines the Routing of CD95 Apoptotic Signaling Pathways , 2004, Cancer Research.
[8] M. J. Abedin,et al. Selective Eosinophil Adhesion to Fibroblast Via IFN-γ-Induced Galectin-9 , 2002, The Journal of Immunology.
[9] G. Gores,et al. Life and death by death receptors , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[10] S. Korsmeyer,et al. Review Cell Death: Critical Control Points Another Line of Evidence for the Importance of Caspases in Cell Death Came From , 2022 .
[11] Igor Rudan,et al. Mechanisms of disease: The human N-glycome. , 2016, Biochimica et biophysica acta.
[12] D. Green,et al. The Pathophysiology of Mitochondrial Cell Death , 2004, Science.
[13] Suzanne Cory,et al. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. , 2007, Current opinion in immunology.
[14] S. Vogel,et al. IFN Regulatory Factor-2 Regulates Macrophage Apoptosis through a STAT1/3- and Caspase-1-Dependent Mechanism1 , 2007, The Journal of Immunology.
[15] P. Stewart,et al. Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. , 1999, Journal of immunology.
[16] H. Handoko,et al. The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma Cells , 2012 .
[17] M. Hirashima,et al. Functional heterogeneity of human eosinophil chemotactic lymphokines. , 1991, Lymphokine and cytokine research.
[18] J. Esko,et al. The sweet and sour of cancer: glycans as novel therapeutic targets , 2005, Nature Reviews Cancer.
[19] T. Niki,et al. 19 Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells , 2015 .
[20] T. Niki,et al. Beneficial effect of galectin 9 on rheumatoid arthritis by induction of apoptosis of synovial fibroblasts. , 2007, Arthritis and rheumatism.
[21] A. Yamauchi,et al. Galectin-9 protects mice from the Shwartzman reaction by attracting prostaglandin E2-producing polymorphonuclear leukocytes. , 2007, Clinical immunology.
[22] M. Lamkanfi,et al. Pyroptosis , 2016, Current Biology.
[23] T. Niki,et al. Galectin-9: An anticancer molecule for gallbladder carcinoma. , 2016, International journal of oncology.
[24] B. Cookson,et al. Anthrax lethal toxin and Salmonella elicit the common cell death pathway of caspase-1-dependent pyroptosis via distinct mechanisms , 2008, Proceedings of the National Academy of Sciences.
[25] E. Zenteno,et al. Identification of Galectin-3 and Mucin-Type O-Glycans in Breast Cancer and Its Metastasis to Brain , 2008, Cancer investigation.
[26] P. Sansonetti,et al. Cytotoxicity and interleukin‐1β processing following Shigella flexneri infection of human monocyte‐derived dendritic cells , 2002, European journal of immunology.
[27] Siew Wui Chan,et al. Changed expression of E-cadherin and galectin-9 in oral squamous cell carcinomas but lack of potential as prognostic markers. , 2014, Asian Pacific journal of cancer prevention : APJCP.
[28] A. Yamauchi,et al. Galectin-9 in physiological and pathological conditions , 2004, Glycoconjugate Journal.
[29] Jessica A. Randall,et al. A Crucial Role for Kupffer Cell-Derived Galectin-9 in Regulation of T Cell Immunity in Hepatitis C Infection , 2010, PloS one.
[30] Y. Sun,et al. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells , 2011, Cell Death and Differentiation.
[31] M. Hirashima,et al. Establishment of a human T-cell line constitutively producing several eosinophil chemotactic lymphokines and their functional heterogeneity on eosinophils. , 1992, Lymphokine and cytokine research.
[32] Tatyana Chernova,et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease , 2002, Nature.
[33] T. Niki,et al. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. , 2008, Clinical immunology.
[34] Toshihiko Oka,et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. , 2002, Biochimica et biophysica acta.
[35] A. Yamauchi,et al. Galectin-9 as a Prognostic Factor with Antimetastatic Potential in Breast Cancer , 2005, Clinical Cancer Research.
[36] Geoff P. O’Donoghue,et al. Investigating Cell Surface Galectin-Mediated Cross-Linking on Glycoengineered Cells , 2012, Journal of the American Chemical Society.
[37] A. Kumar,et al. Developmental regulation, expression, and apoptotic potential of galectin-9, a beta-galactoside binding lectin. , 1997, The Journal of clinical investigation.
[38] A. Helenius,et al. Intracellular functions of N-linked glycans. , 2001, Science.
[39] A. Strasser,et al. The BCL-2 protein family, BH3-mimetics and cancer therapy , 2015, Cell Death and Differentiation.
[40] H. Kita,et al. Biological Activities of Ecalectin: A Novel Eosinophil-Activating Factor1 , 2002, The Journal of Immunology.
[41] A. Aderem,et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria , 2010, Nature Immunology.
[42] B. Klapp,et al. Profiling Lgals9 Splice Variant Expression at the Fetal-Maternal Interface: Implications in Normal and Pathological Human Pregnancy1 , 2013, Biology of reproduction.
[43] A. Surolia,et al. Lectin microarrays for glycomic analysis. , 2010, Omics : a journal of integrative biology.
[44] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[45] A. Hoeflich,et al. Gene expression of galectin-9/ecalectin, a potent eosinophil chemoattractant, and/or the insertional isoform in human colorectal carcinoma cell lines and detection of frame-shift mutations for protein sequence truncations in the second functional lectin domain. , 2000, International Journal of Oncology.
[46] T. Niki,et al. Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest. , 2015, Oncology reports.
[47] L. Baum,et al. Ah, sweet mystery of death! Galectins and control of cell fate. , 2002, Glycobiology.
[48] M. Hirashima,et al. Regulation of galectin-9 expression and release in Jurkat T cell line cells. , 2002, Glycobiology.
[49] M. Hirashima,et al. Persistent elevation of plasma osteopontin levels in HIV patients despite highly active antiretroviral therapy. , 2009, The Tohoku journal of experimental medicine.
[50] G. Majno,et al. Apoptosis, oncosis, and necrosis. An overview of cell death. , 1995, The American journal of pathology.
[51] J. Mottram,et al. Comparative structural analysis of the caspase family with other clan CD cysteine peptidases , 2015, The Biochemical journal.
[52] R A Knight,et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012 , 2011, Cell Death and Differentiation.
[53] Y. Kanwar,et al. Identification and Characterization of Galectin-9, a Novel β-Galactoside-binding Mammalian Lectin* , 1997, The Journal of Biological Chemistry.
[54] 加塩 裕美子. Galectin-9 induces apoptosis through calcium-calpain-caspase-1 pathway , 2003 .
[55] A. Griffioen,et al. Galectin-9 in tumor biology: a jack of multiple trades. , 2013, Biochimica et biophysica acta.
[56] G. Steel,et al. The growth rate of human tumours. , 1966, British Journal of Cancer.
[57] A. Wyllie,et al. Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.
[58] Soichi Wakatsuki,et al. Crystal Structure of the Galectin-9 N-terminal Carbohydrate Recognition Domain from Mus musculus Reveals the Basic Mechanism of Carbohydrate Recognition* , 2006, Journal of Biological Chemistry.
[59] L. Earl,et al. Galectin multimerization and lattice formation are regulated by linker region structure. , 2011, Glycobiology.
[60] O. Iversen. Kinetics of cellular proliferation and cell loss in human carcinomas. A discussion of methods available for in vivo studies. , 1967, European journal of cancer.
[61] T. Niki,et al. The Glycan-Binding Protein Galectin-9 Has Direct Apoptotic Activity toward Melanoma Cells , 2012, The Journal of investigative dermatology.
[62] S. Lowe,et al. Intrinsic tumour suppression , 2004, Nature.
[63] M. J. Abedin,et al. Galectin-9 Induces Apoptosis Through the Calcium-Calpain-Caspase-1 Pathway1 , 2003, The Journal of Immunology.
[64] J. Piette,et al. SHIP-1 inhibits CD95/APO-1/Fas-induced apoptosis in primary T lymphocytes and T leukemic cells by promoting CD95 glycosylation independently of its phosphatase activity , 2010, Leukemia.
[65] M. F. Troncoso,et al. Hierarchical and selective roles of galectins in hepatocarcinogenesis, liver fibrosis and inflammation of hepatocellular carcinoma. , 2013, World journal of gastroenterology.
[66] M. Hirashima,et al. Human Ecalectin, a Variant of Human Galectin-9, Is a Novel Eosinophil Chemoattractant Produced by T Lymphocytes* , 1998, The Journal of Biological Chemistry.
[67] H. Yoshida,et al. X-ray Structures of Human Galectin-9 C-terminal Domain in Complexes with a Biantennary Oligosaccharide and Sialyllactose* , 2010, The Journal of Biological Chemistry.
[68] G. Rabinovich,et al. Glycobiology of cell death: when glycans and lectins govern cell fate , 2013, Cell Death and Differentiation.
[69] J. Suo,et al. Decreased Galectin-9 and Increased Tim-3 Expression Are Related to Poor Prognosis in Gastric Cancer , 2013, PloS one.
[70] T. Niki,et al. Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo. , 2015, International journal of oncology.
[71] J. Graessler,et al. Molecular and functional characterization of galectin 9 mRNA isoforms in porcine and human cells and tissues. , 2001, Biochimie.
[72] B. Cookson,et al. Pro-inflammatory programmed cell death. , 2001, Trends in microbiology.
[73] M. Hirashima,et al. Exosomes released by EBV-infected nasopharyngeal carcinoma cells convey the viral Latent Membrane Protein 1 and the immunomodulatory protein galectin 9 , 2006, BMC Cancer.
[74] Tatjana Crnogorac-Jurcevic,et al. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. , 2002, The American journal of pathology.
[75] M. Pfreundschuh,et al. Molecular Definition of a Novel Human Galectin Which Is Immunogenic in Patients with Hodgkin's Disease* , 1997, The Journal of Biological Chemistry.
[76] R. Khosravi‐Far,et al. Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities , 2008, Journal of cellular biochemistry.
[77] 森脇 健太,et al. Deficiency of GMDS Leads to Escape from NK Cell-Mediated Tumor Surveillance Through Modulation of TRAIL Signaling , 2010 .
[78] T. Niki,et al. Effect of nasopharyngeal carcinoma-derived exosomes on human regulatory T cells. , 2015, Journal of the National Cancer Institute.
[79] M. Hirashima,et al. Requirement of Divalent Galactoside-binding Activity of Ecalectin/Galectin-9 for Eosinophil Chemoattraction* , 2000, The Journal of Biological Chemistry.
[80] James C Paulson,et al. Cell surface biology mediated by low affinity multivalent protein-glycan interactions. , 2004, Current opinion in chemical biology.
[81] Y. St-Pierre,et al. Intracellular galectins in cancer cells: potential new targets for therapy (Review). , 2014, International journal of oncology.
[82] F. Bard,et al. Short O-GalNAc glycans: regulation and role in tumor development and clinical perspectives. , 2016, Biochimica et biophysica acta.
[83] K. Smetana,et al. Immunohistochemical fingerprinting of the network of seven adhesion/growth-regulatory lectins in human skin and detection of distinct tumour-associated alterations. , 2009, Folia biologica.
[84] L. Baum,et al. Galectin-glycan lattices regulate cell-surface glycoprotein organization and signalling. , 2008, Biochemical Society transactions.
[85] M. Hirashima,et al. Development of highly stable galectins: Truncation of the linker peptide confers protease‐resistance on tandem‐repeat type galectins , 2005, FEBS letters.
[86] Xian-qiang Wang,et al. Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma. , 2012, Asian Pacific journal of cancer prevention : APJCP.
[87] E. Miyoshi,et al. GDP-mannose-4,6-dehydratase (GMDS) Deficiency Renders Colon Cancer Cells Resistant to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Receptor- and CD95-mediated Apoptosis by Inhibiting Complex II Formation* , 2011, The Journal of Biological Chemistry.
[88] L. Earl,et al. Structural Features of Galectin-9 and Galectin-1 That Determine Distinct T Cell Death Pathways* , 2008, Journal of Biological Chemistry.
[89] J. Sacchettini,et al. Multivalent protein-carbohydrate interactions. A new paradigm for supermolecular assembly and signal transduction. , 2001, Biochemistry.
[90] G. Salvesen,et al. Mechanisms of caspase activation. , 2003, Current opinion in cell biology.
[91] P. Matarrese,et al. Galectin-1 Sensitizes Resting Human T Lymphocytes to Fas (CD95)-mediated Cell Death via Mitochondrial Hyperpolarization, Budding, and Fission* , 2005, Journal of Biological Chemistry.
[92] L. French,et al. Caspase-1 activity is required for UVB-induced apoptosis of human keratinocytes. , 2015, The Journal of investigative dermatology.
[93] Alexei Degterev,et al. A decade of caspases , 2003, Oncogene.
[94] T. Masaki,et al. Galectin-9 suppresses the proliferation of gastric cancer cells in vitro. , 2016, Oncology reports.
[95] P. Krammer,et al. Modulation of the CD95-Induced Apoptosis: The Role of CD95 N-Glycosylation , 2011, PloS one.
[96] M. Taniwaki,et al. Targeting Activating Transcription Factor 3 by Galectin-9 Induces Apoptosis and Overcomes Various Types of Treatment Resistance in Chronic Myelogenous Leukemia , 2010, Molecular Cancer Research.
[97] J. Rappaport,et al. Molecular Cloning and Functional Reconstitution of a Urate Transporter/Channel* , 1997, The Journal of Biological Chemistry.
[98] M. J. Abedin,et al. Possible role of galectin‐9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance , 2002, International journal of cancer.
[99] M. Taniwaki,et al. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways , 2010, Leukemia.
[100] V. Kuchroo,et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity , 2005, Nature Immunology.
[101] S. Willis,et al. Life in the balance: how BH3-only proteins induce apoptosis. , 2005, Current opinion in cell biology.
[102] T. Niki,et al. Cell Surface Galectin-9 Expressing Th Cells Regulate Th17 and Foxp3+ Treg Development by Galectin-9 Secretion , 2012, PloS one.
[103] V. Najfeld,et al. Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. , 2001, The Journal of clinical investigation.
[104] J. Hirabayashi,et al. Functional analysis of the carbohydrate recognition domains and a linker peptide of galectin-9 as to eosinophil chemoattractant activity. , 2002, Glycobiology.
[105] J. Suo,et al. Role of downregulation of galectin-9 in the tumorigenesis of gastric cancer. , 2014, International journal of oncology.
[106] A. Griffioen,et al. The galectin profile of the endothelium: altered expression and localization in activated and tumor endothelial cells. , 2008, The American journal of pathology.
[107] S. Refsum,et al. Cell loss in malignant tumours in man. , 1967, European journal of cancer.
[108] J. Kutok,et al. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. , 2013, Cancer research.